Molecular imaging developer Sofie Biosciences is slated to receive awards totaling $5 million through the Small Business Innovation Research (SBIR) program at the U.S. National Institutes of Health (NIH).
The NIH is awarding Sofie the following three grants:
- A $2 million phase IIB award from the National Institute of Mental Health for the development of a microfluidic-based radiosynthesizer that can make PET tracers on demand for brain imaging
- Another $2 million phase IIB award from the National Cancer Institute for the use of Sofie's Elixys automated radiochemical synthesizer in a clinical trial investigating a new potential diagnostic PET tracer for imaging immune response
- A $1 million phase II award from the National Institute of Biomedical Imaging and Bioengineering -- in partnership with the University of California, San Francisco -- for the development of technology capable of producing diagnostic PET tracers known as radiofluorinated proteins
